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Nonstandard Abbreviations and Acronyms 
IAS inherited arrhythmia syndromes 
SCA sudden cardiac arrest 
LQTS long-QT syndrome 
BrS Brugada syndrome 
ERS early repolarization syndrome 
CPVT catecholaminergic polymorphic ventricular tachycardia 
IVF idiopathic ventricular fibrillation 
VT ventricular tachycardia 




The inherited arrhythmia syndromes (IAS) are a group of genetic heart diseases predisposing 
to sudden cardiac arrest (SCA).
1 
Patients with IAS and their family members receive 
diagnostic and therapeutic management, which is heterogeneous across centres and 
suboptimal with regard to adherence to current guidelines. In particular, genetic testing, which 
is of utmost importance for its implications in the treatment of some IAS (i.e. long-QT 
syndrome, LQTS), is not always performed.
2, 3 
The data that support the findings of this study are available from the European Heart 
Rhythm Association (EHRA) upon reasonable request.  Additionally, IRB approval was 
obtained by EHRA. 
The aim of this European Heart Rhythm Association (EHRA) survey analysis was to 
evaluate the relationship between the presence of dedicated IAS units, center volume and 
management of patients with IAS. The EHRA Scientific Initiatives Committee conducted the 
present survey in collaboration with the European Cardiac Arrhythmia Genetics’ Focus Group 
3 
(ECGen) and ERN GUARD-Heart. A center-based on-line questionnaire was constructed to 
collect information about presence of dedicated IAS units, center volume and diagnostic and 
therapeutic management of patients with the following diseases: Brugada syndrome (BrS), 
long-QT syndrome (LQTS), early repolarization syndrome (ERS), catecholaminergic 
polymorphic ventricular tachycardia (CPVT), and idiopathic ventricular fibrillation (IVF). 
Dedicated IAS unit was defined by the presence at a given Institution of a structured 
multidisciplinary service, including electrophysiologists specialized in IAS, device specialists, 
genetic counsellors, and psychiatric support, for the management of patients and their family 
members who have a confirmed diagnosis or who are seeking an opinion regarding a possible 
diagnosis of IAS. The link was sent out to the EHRA Research Network Centres and ECGen 
members. Forty-four European centers were included in the analysis: 27 (61%) had a 
dedicated unit for the management of IAS patients while there was no dedicated unit in the 
remaining 17 (39%) (Table 1). Out of 27 centers with dedicated units, 10 (37%) managed 
more than 100 patients in the previous 12 months, whereas all centers without a dedicated unit 
had lower volumes. Moreover, centers without a dedicated unit were more likely to have very 
low volumes (<20 patients/year) of adults (7% vs 47%, p<0.01) and pediatric patients (41% 
vs. 87%, p: 0.03). There were no significant differences between centres on the use of 
pharmacological challenges in the diagnostic assessment of IAS. However, centers without a 
dedicated unit performed less genetic testing for all the different types of IAS, including those 
where a genetic diagnosis can influence therapeutic choices. Specifically, genetic testing for 
LQTS was performed in 92% and 59% of centres with and without dedicated units, 
respectively (p: 0.01). Centers with a dedicated unit were more likely to perform an 
electrophysiology study with programmed ventricular stimulation for risk stratification (71% 
vs. 41%) and substrate ablation procedures (82% vs. 53%) for patients with Brugada 
syndrome. 
4 
In conclusion, dedicated IAS units frequently combine specialized care for adult and 
pediatric patients, genetic testing and specific diagnostic and therapeutic procedures more 
frequently compared to centers with a low volume. However, treatment/outcome superiority 
of IAS units was not examined in this survey. In the 2011 HRS/EHRA consensus statement 
on the state of art of genetic testing and 2013 HRS/EHRA/APHRS expert consensus on the 
diagnosis and management of IAS, genetic testing was recommended for probands with a 
clinical diagnosis and for all family members of a successfully genotyped proband (Class I 
recommendation).
1, 2
 In LQTS, the risk of life-threatening arrhythmic events, which is 
modulated by the duration of QTc interval and the genetic substrate, is not equal for all 
patients.
4
 Specific gene mutations are associated with different arrhythmic risk and potential 
therapeutic benefits. Therefore, genetic testing in these patients has important prognostic 
implications due to the interplay between genetic substrate, QTc duration, and arrhythmia risk 
and impact on the response to pharmacotherapy.
4
 Patients with LQTS not undergoing genetic 
testing may therefore not receive an appropriate therapeutic approach. Moreover, genetic 
testing, including pre- and post- genetic testing counselling, is valuable for identifying 
variants within genes known to be associated with increased risk for disease features and 
allows for predictive testing of at-risk family members.
2, 3, 5
 According to this survey’s results, 
underuse of genetic testing is more likely to occur in centers without dedicated IAS units. 
Therefore, we make strong plea for institutions to commit the creation and implementation of 
dedicated IAS units or, otherwise refer these patients to dedicated centers where they and 
their families can be seen in a multidisciplinary setting.
3
 Further efforts to improve patient 
care in this setting are strongly warranted. 
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Table 1. Patient volume of centers with and without IAS units and the related patients’ management. 
 
 Centers with IAS units (N=27) Centers without IAS units (N=17) p-value 




















Number of centres managing pediatric patients  22 (81%) 8 (47%) 0.02 





















- Pharmacological challenge 
- Genetic testing 
- Electrophysiology study 
- Ventricular arrhythmogenic substrate ablation 























- Pharmacological challenge 










Early repolarization syndrome 
- Pharmacological challenge 










Catecholaminergic polymorphic VT 
- Pharmacological challenge  











- Pharmacological challenge  










IAS inherited arrhythmia syndromes; VT ventricular tachycardia; VF ventricular fibrillation 
